



Date: 16.11.2025

To Listing Department National Stock Exchange of India Ltd. Exchange Plaza, Plot No. C, Block G, Bandra Kurla Complex, Bandra (E), Mumbai-400051 Symbol: AVROIND	To Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 BSE Scrip Code: 543512
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------

Sub: Publication of Unaudited Financial Results for the Quarter and Half year ended 30th September, 2025.

Dear Sir/Mam

In terms of Regulation 47(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has published the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September, 2025 in all editions of Financial Express (English) and in Jansatta (Hindi).

Further, in pursuance of Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed extracts of Newspaper advertisements as published in the above mentioned newspapers.

Kindly take the above information on your records and oblige.

Thanking You

Yours Faithfully,

For AVRO INDIA LIMITED

**Sumit Bansal
(Company Secretary & Compliance Officer)
Membership No-A42433**

Encl: As above

AVRO INDIA LIMITED

Registered Office: A-7/36-39, South of G.T Road Industrial Area, Electrosteel Casting Compound, Ghaziabad-201009, Uttar Pradesh

Email: support@avrofurniture.com | Website: www.avrofurniture.com | Helpline No: 9910039125

CIN: L25200UP1996PLC101013

मज़बूत कुर्सी मतलब ऐव्रो कुर्सी



AANCHAL ISPAT LIMITED

Registered Office: Mouza - Chammal, NH 6, Howrah, West Bengal - 711114
Email: info@aanchalspat.com, Tel: 03212-246121, Website: www.aanchalspat.com

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2025 (Rs in Lakhs except EPS)

PARTICULARS	Quarter ended	Half Year ended	Quarter ended	Year ended
	30.09.2025 (Unaudited)	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
Total Income from Operations (net)	1,877.90	2,272.18	3,874.08	15,130.13
Net Profit/(Loss) for the period (Before tax Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(535.38)
Net Profit/(Loss) for the period before tax (After Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(1,790.76)
Net Profit/(Loss) for the period after tax (After Exceptional and/or Extraordinary items)	21.14	4.74	(15.35)	(1,340.23)
Total Comprehensive Income for the period after tax and Other Comprehensive Income (after tax)	21.14	4.74	(15.35)	(1,334.96)
Equity Share Capital	283.33	283.33	2,085.38	2,085.38
Other Equity (excluding Revaluation Reserve as shown in the Balance sheet of previous year)	-	-	-	(1,740.26)
Earning Per Share (Rs.10/- each)	0.75	0.17	(0.07)	(6.40)
Basic: (in Rs)	0.75	0.17	(0.07)	(6.40)
Diluted: (in Rs)	0.75	0.17	(0.07)	(6.40)

Notes :

- The above is an extract of the detailed format of Quarter and half year ended 30th September, 2025 unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the quarter and half year ended Financial Results are available on the BSE website - www.bseindia.com and on the Company website <http://www.aanchalspat.com/financials.html#financials>
- The above results have been prepared in accordance with Indian Accounting Standards ("IND AS") notified under section 133 of the Companies Act 2013 read together with the Companies (Indian Accounting Standards) Rules, 2015.



For Aanchal Ispat Limited
Sd/-
Mukesh Goel
(Managing Director)

Place : Kolkata
Date : 14.11.2025

BRAWN BIOTECH LIMITED

CIN:L74899DL1985PLC022468

REGD. OFFICE: C-64, Lajpat Nagar-I, New Delhi 110024

Extract of Standalone Un-Audited Financial Results for the quarter and half year ended 30th September 2025 (Rs. In Lakhs)

Sl. No.	Particulars	Standalone								
		Quarter Ended	Half-yearly ended	Year Ended	30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	30-Sep-24	31-Mar-25
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Audited	Audited
1	Total income from operation	498.22	588.86	329.81	1,087.08	736.22	1,355.83			
2	Net Profit/(Loss) from ordinary activities after tax	7.14	23.60	(34.37)	30.74	(87.18)	(179.81)			
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	7.14	23.60	(34.37)	30.74	(87.18)	(179.81)			
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	7.49	26.80	(28.66)	34.30	(83.44)	(176.08)			
5	Equity Share Capital	300.03	300.03	300.03	300.03	300.03	300.03			
6	Reserve (excluding Revaluation Reserves as shown in the Balance sheet of previous year)									
7	Earning per share (before extraordinary items) (not annualised): (of rs. 10 each)									
	(a) Basic (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87			
	(b) Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87			
8	Earning per share (after extraordinary items) (not annualised): (of rs. 10 each)									
	(a) Basic (Rs.)	0.25	0.89	(0.96)	1.14	(2.78)	(5.87)			
	(b) Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87			

NOTES :

- The above is an extract of the detailed format of Quarterly and Half Yearly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiotech.com).
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14-11-2025.
- The Financials have been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ind-AS) to the extent applicable. The Company has for the first time adopted Ind-AS beginning 01st April 2017 with transition date of 01st April, 2016.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.



For and on behalf of Board
For Brown Biotech Limited
Sd/-
Brij Raj Gupta
Director
DIN NO. 00974969

Place : Delhi
Date : 14-11-2025

ECOBX INDUSTRIALS ASSET II PRIVATE LIMITED

[Now merged with INDO SPACE CHITTOOR PRIVATE LIMITED]

Corporate Identity Number: U45203MH2014PTC252644

HD-731, WeWork Vaswani Chambers, 2nd Floor, 264-265, Dr Annie Besant Rd, Municipal Colony,

Worli Shivaji Nagar, Worli, Mumbai, Maharashtra 400030

Tel: +91 9167736898 | E-mail: Compliance@ecoboxi.com | Website: www.ecoboxi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2025

Sr. No.	Particulars	(Rs. In Lakhs)			
		Quarter Ended	Six Months Ended	Year Ended	
		30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	30 September 2025 (Unaudited)	31 March 2025 (Audited)
1	Total Income from operations	477.97	-	1,031.97	-
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	-518.39	-3.50	-996.08	-3.50
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	-518.39	-3.50	-996.08	-3.50
6	Paid up Equity Share Capital	10.00	10.00	10.00	10.00
7	Reserves (excluding Revaluation Reserve)	-746.84	-3.50	-746.84	-3.50
8	Securities Premium Account	-	-	-	-
9	Net worth	-736.84	6.50	-736.84	6.50
10	Paid up Debt Capital/ Outstanding Debt	23,906.87	-	23,906.87	-
11	Outstanding Redeemable Preference Shares	-	-	-	-
12	Debt Equity Ratio	-32.45	-1.31	-32.45	-90.09
13	Earnings per Share (of Rs.10/- each):				
	1. Basic:	-518.39	-2,160.89	-996.08	-2,160.89
	2. Diluted:	-518.39	-2,160.89	-996.08	-2,160.89
14	Capital Redemption Reserve	NA	NA	NA	NA
15	Debtors Redemption Reserve	NA	NA	NA	NA
16	Debt Service Coverage Ratio	0.60	NA	0.65	NA
17	Interest Service Coverage Ratio	0.61	NA	0.65	NA

1. Net worth = Share capital + Reserves & Surplus – Deferred Tax Assets

2. Paid-up Debt Capital/ Outstanding Debt = Total Debt

3. Debt Equity Ratio = Total Debt / Net worth

4. DSCR = (Profit before interest and tax) / (Interest expense)

5. ISCR = Profit before interest and tax / Interest expense

Notes:
1.The above is an extract of the detailed format of quarter and period ended financial results filed with the Stock Exchanges in accordance with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), as amended. The full format of quarter and period ended financial results are available on the websites of the Stock exchange and the Company's website (www.ecoboxi.com).
2.For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange and the Company's website (www.ecoboxi.com).
3.The Company received the approval order dated July 17, 2025, from the Regional Director, Western Region, for the Scheme of Amalgamation under Section 233 of the Companies Act, 2013, involving the merger of Ecobox Industrials Asset II Private Limited (Transferor Company / Holding Company) with Indo Space Chittoor Private Limited (Transferee Company / Company) which is effective from November 06, 2024 (appointed date i.e. the acquisition date). The Company has completed all requisite filings with the Registrar of Companies to give effect to the scheme, in accordance with the merger order. The merger has been accounted for as a reverse acquisition in accordance with Ind AS 103 'Business Combinations', with Indo Space Chittoor II Private Limited identified as the acquiring company. Accordingly, comparative figures are restated to give the effect of the merger from the appointed date.
4.The above financial results of the Company are reviewed and have been approved by the Board of Directors of the Company at their respective meeting held on November 14, 2025. The Statutory Auditors have conducted limited review and have issued an unmodified report on the financial results for the quarter and period ended September 30, 2025.

For INDO SPACE CHITTOOR PRIVATE LIMITED

Ashish Shah

Director

DIN - 065898999

Date : 14 Nov. 2025

Place: Mumbai

Registered Office:
No. 258/A, Bommasandra Industrial Area, Anekal Taluk,
Bengaluru- 560 099 , Karnataka, India.
Telephone: +91-8050009318
Email : investorrelations@narayanahealth.org

Narayana Health
Narayana Hrudayalaya Limited
www.narayanahealth.org
CIN:L85110KA2000PLC027497

EXTRACT OF



Narayana Hrudayalaya Limited
www.narayanahealth.org
CIN:L85110KA2000PLC027497

AANCHAL ISPAT LIMITED

CIN: L27106WB1996PLC076866

Registered Office: Mouza - Charnail, NH 6, Howrah, West Bengal - 711114
Email: info@aanchalspat.com, Tel: 03212-246121, Website: www.aanchalspat.com

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2025 (Rs in Lakhs except EPS)

PARTICULARS	Quarter ended 30.09.2025	Half Year ended 30.09.2025	Quarter ended 30.09.2024	Year ended 31.03.2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations (net)	1,877.90	2,272.18	3,874.08	15,130.13
Net Profit/(Loss) for the period (Before tax Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(535.38)
Net Profit/(Loss) for the period before tax (After Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(1,790.76)
Net Profit/(Loss) for the period after tax (After Exceptional and/or Extraordinary items)	21.14	4.74	(15.35)	(1,340.23)
Total Comprehensive Income for the period after tax and Other Comprehensive Income (after tax)	21.14	4.74	(15.35)	(1,334.96)
Equity Share Capital	283.33	283.33	2,085.38	2,085.38
Other Equity (excluding Revaluation Reserve as shown in the Balance sheet of previous year)	-	-	-	(1,740.26)
Earning Per Share (Rs.10/- each)	0.75	0.17	(0.07)	(6.40)
Diluted: (in Rs)	0.75	0.17	(0.07)	(6.40)

Notes :

- 1 The above is an extract of the detailed format of Quarter and half year ended 30th September, 2025 unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the quarter and half year ended Financial Results are available on the BSE website: www.bseindia.com and on the Company website <http://www.aanchalspat.com/financials.html#financials>
- 2 The above results have been prepared in accordance with Indian Accounting Standards ("IND AS") notified under section 133 of the Companies Act 2013 read together with the Companies (Indian Accounting Standards) Rules, 2015.



For Aanchal Ispat Limited
Sd/-
Mukesh Goel
(Managing Director)

Place : Kolkata
Date : 14.11.2025

BRAWN BIOTECH LIMITED

CIN:L74899DL1985PLC022468

REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

Extract of Standalone Un-Audited Financial Results for the quarter and half year ended 30th September 2025 (Rs. In Lakhs)

Sl. No.	Particulars	Standalone				
		Quarter Ended		Half-yearly ended		Year Ended
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	31-Mar-25
1	Total income from operation	498.22	588.86	329.81	1,087.08	736.22
2	Net Profit/(Loss) from ordinary activities after tax	7.14	23.60	(34.37)	30.74	(87.18)
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	7.14	23.60	(34.37)	30.74	(87.18)
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	7.49	26.80	(28.66)	34.30	(83.44)
5	Equity Share Capital	300.03	300.03	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year)					
7	Earning per share (before extraordinary items) (not annualised): (of rs. 10 each)					
(a)	Basic (Rs.)	0.25	0.89	-0.96	1.14	-2.78
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78
8	Earning per share (after extraordinary items) (not annualised): (of rs. 10 each)					
(a)	Basic (Rs.)	0.25	0.89	(0.96)	1.14	(2.78)
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78

- NOTES :
- The above is an extract of the detailed format of Quarterly and Half Yearly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiootech.com).
 - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14-11-2025.
 - The Financials have been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ind-AS) to the extent applicable. The Company has for the first time adopted Ind-AS beginning 01st April 2017 with transition date of 01st April, 2016.
 - The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
 - Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.



For and on behalf of Board
For Brawn Biotech Limited
Sd/-
Brij Raj Gupta
Director
DIN NO. 00974969

Place : Delhi
Date : 14-11-2025

ECOBOX INDUSTRIALS ASSET II PRIVATE LIMITED

[Now merged with INDO SPACE CHITTOOR PRIVATE LIMITED]

Corporate Identity Number: U45203MH2014PTC252644

HD-731, WeWork Vaswani Chambers, 2nd Floor, 264-265, Dr Annie Besant Rd, Municipal Colony, Worli Shivaji Nagar, Worli, Mumbai, Maharashtra 400030

Tel.: +91 9167736898 | E-mail: Compliance@ecoboxi.com | Website: www.ecoboxi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR

THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2025

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended		Six Months Ended		Year Ended
		30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	31 March 2025 (Audited)
1	Total Income from operations	477.97	-	1,031.97	-	809.69
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	-518.39	-3.50	-996.08	-3.50	-1,266.61
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	-518.39	-3.50	-996.08	-3.50	-1,266.61
6	Paid up Equity Share Capital	10.00	10.00	10.00	10.00	10.00
7	Reserves (Excluding Revaluation Reserve)	-746.84	-3.50	-746.84	-3.50	249.24
8	Securities Premium Account	-	-	-	-	-
9	Net worth	-736.84	6.50	-736.84	6.50	259.24
10	Paid up Debt Capital/ Outstanding Debt	23,906.87	-	23,906.87	-	23,354.83
11	Outstanding Redeemable Preference Shares	-	-	-	-	-
12	Debt Equity Ratio	-32.45	-1.31	-32.45	-	90.09
13	Earnings Per Share (Rs.10/- each)-					
1. Basic	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
2. Diluted:	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
14	Capital Redemption Reserve	NA	NA	NA	NA	NA
15	Debt Service Coverage Ratio	NA	NA	NA	NA	NA
16	Debt Equity Ratio	0.60	NA	0.65	NA	0.42
17	Interest Service Coverage Ratio	0.61	NA	0.65	NA	0.43

1. Net worth = Share capital + Reserves & Surplus - Deferred Tax Assets

2. Paid-up Debt Capital/ Outstanding Debt = Total Debt

3. Debt Equity Ratio = Total Debt / Net worth

4. DSCR = (Profit before interest and tax) / (Interest expense)

5. ISCR = Profit before interest and tax / Interest expense

Notes: 1. The above is an extract of the detailed format of quarter and period ended financial results filed with the Stock Exchanges in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), as amended. The full format of quarter and period ended financial results are available on the websites of the Stock exchange and the Company's website (www.ecoboxi.com). 2. For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange and the Company's website (www.ecoboxi.com). 3. The Company received the approval order dated July 17, 2025, from the Regional Director, Western Region, for the Scheme of Amalgamation under Section 233 of the Companies Act, 2013, involving the merger of Ecobox Industrials Asset II Private Limited (Transferor Company / Holding Company) with Indo Space Chittoor Private Limited (Transferee Company / Company) which is effective from November 06, 2024 (appointed date i.e. the acquisition date). The Company has completed all requisite filings with the Registrar of Companies to give effect to the scheme, in accordance with the merger order. The merger has been accounted for as a reverse acquisition in accordance with Ind AS 103 'Business Combinations', with Indo Space Chittoor II Private Limited identified as the accounting acquiree. Accordingly, comparative figures are restated to give the effect of the merger from the appointed date. 4. The above financial results of the Company are reviewed and have been approved by the Board of Directors of the Company at their respective meeting held on November 14, 2025. The Statutory Auditors have conducted limited review and have issued an unmodified report on the financial results for the quarter and period ended September 30, 2025. For INDO SPACE CHITTOOR PRIVATE LIMITED Ashish Shah Director DIN : 06989999 Date : 14 Nov, 2025 Place : Mumbai

Registered Office:
No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru- 560 099 , Karnataka, India.
Telephone: +91-8050009318
Email : investorrelations@narayanahealth.org

Narayana Hrudayalaya Limited
www.narayanahealth.org
CIN:L85110KA2000PLC027497

EXTRACT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2025

(\$ in Million, except per share data)

Sl. No.	Particulars	Standalone				Consolidated			
Quarter ended 30.09.2025	Quarter ended 30.09.2024	Half Year ended 30.09.2025	Year ended 31.03.2025	Quarter ended 30.09.2025	Quarter ended 30.09.2024	Half Year ended 30.09.2025	Year ended 31.03.2025		
Un-audited	Un-audited	Un-audited	Audited	Un-audited	Un-audited	Un-audited	Audited		

<tbl_r cells="



Narayana Hrudayalaya Limited
www.narayanahealth.org
CIN:L85110KA2000PLC027497

AANCHAL ISPAT LIMITED

CIN: L27106WB1996PLC076866

Registered Office: Mouza - Chamrai, NH 6, Howrah, West Bengal - 711114
Email: info@aanchalspat.com, Tel: 03212-246121, Website: www.aanchalspat.com

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2025

(Rs in Lakhs except EPS)

PARTICULARS	Quarter ended 30.09.2025	Half Year ended 30.09.2025	Quarter ended 30.09.2024	Year ended 31.03.2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations (net)	1,877.90	2,272.18	3,874.08	15,130.13
Net Profit/(Loss) for the period (Before tax Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(535.38)
Net Profit/(Loss) for the period before tax (After Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(1,790.76)
Net Profit/(Loss) for the period after tax (After Exceptional and/or Extraordinary items)	21.14	4.74	(15.35)	(1,340.23)
Total Comprehensive Income for the period after tax and Other Comprehensive Income (after tax)	21.14	4.74	(15.35)	(1,334.96)
Equity Share Capital	283.33	283.33	2,085.38	2,085.38
Other Equity (excluding Revaluation Reserve as shown in the Balance sheet of previous year)	-	-	-	(1,740.26)
Earning Per Share (Rs.10/- each)	0.75	0.17	(0.07)	(6.40)
Diluted: (in Rs)	0.75	0.17	(0.07)	(6.40)

Notes :

- The above is an extract of the detailed format of Quarter and half year ended 30th September, 2025 unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the quarter and half year ended Financial Results are available on the BSE website- www.bseindia.com and on the Company website <http://www.aanchalspat.com/financials.html#financials>
- The above results have been prepared in accordance with Indian Accounting Standards ("IND AS") notified under section 133 of the Companies Act 2013 read together with the Companies (Indian Accounting Standards) Rules, 2015.



For Aanchal Ispat Limited
Sd/-
Mukesh Goel
(Managing Director)

Place : Kolkata

Date : 14.11.2025

BRAWN BIOTECH LIMITED

CIN:L74899DL1985PLC022468

REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

Extract of Standalone Un-Audited Financial Results for the quarter and half year ended 30th September 2025

(Rs. In Lacs)

Sl. No.	Particulars	Standalone					
		Quarter Ended		Half-yearly ended		Year Ended	
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	30-Sep-24	31-Mar-25
1	Total income from operation	498.22	588.86	329.81	1,087.08	736.22	1,355.83
2	Net Profit/(Loss) from ordinary activities after tax	7.14	23.60	(34.37)	30.74	(87.18)	(179.81)
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	7.14	23.60	(34.37)	30.74	(87.18)	(179.81)
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	7.49	26.80	(28.66)	34.30	(83.44)	(176.08)
5	Equity Share Capital	300.03	300.03	300.03	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year)						
7	Earning per share (before extraordinary items) (not annualised): (of rs. 10 each)						
(a)	Basic (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87
8	Earning per share (after extraordinary items) (not annualised): (of rs. 10 each)						
(a)	Basic (Rs.)	0.25	0.89	(0.96)	1.14	(2.78)	(5.87)
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87

- NOTES :
- The above is an extract of the detailed format of Quarterly and Half Yearly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbio.com).
 - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14-11-2025.
 - The Financials have been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ind-AS) to the extent applicable. The Company has for the first time adopted IND-AS beginning 01st April 2017 with transition date of 01st April, 2016.
 - The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
 - Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.



For and on behalf of Board
For Brawn Biotech Limited
Sd/-
Brij Raj Gupta
Director
DIN NO. 00974969

Place : Delhi

Date : 14-11-2025

ECOBX INDUSTRIALS ASSET II PRIVATE LIMITED

[Now merged with INDO SPACE CHITTOOR PRIVATE LIMITED]

Corporate Identity Number: U45203MH2014PTC252644

HD-731, WeWork Vaswani Chambers, 2nd Floor, 264-265, Dr Annie Besant Rd, Municipal Colony,

Worli Shivaji Nagar, Worli, Mumbai, Maharashtra 400030

Tel.: +91 9167736898 | E-mail: Compliance@ecoboxi.com | Website: www.ecoboxi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR

THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2025

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended		Six Months Ended		Year Ended
		30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	31 March 2025 (Audited)
1	Total Income from operations	477.97	-	1,031.97	-	809.69
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	-518.39	-3.50	-996.08	-3.50	-1,266.61
5	Total Comprehensive Income for the period (Comprising Profit/Loss) for the period (after tax) and Other Comprehensive Income (after tax)	-518.39	-3.50	-996.08	-3.50	-1,266.61
6	Paid up Equity Share Capital	10.00	10.00	10.00	10.00	10.00
7	Reserves (excluding Revaluation Reserve)	-746.84	-3.50	-746.84	-3.50	249.24
8	Securities Premium Account	-	-	-	-	-
9	Net worth	-736.84	6.50	-736.84	6.50	259.24
10	Paid up Debt Capital/ Outstanding Debt	23,906.87	-	23,906.87	-	23,354.83
11	Outstanding Redeemable Preference Shares	-	-	-	-	-
12	Debt Equity Ratio	-32.45	-1.31	-32.45	-	90.09
13	Earnings Per Share (of Rs.10/- each)-					
1. Basic:	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
2. Diluted:	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
14	Capital Redemption Reserve	NA	NA	NA	NA	NA
15	Debenture Redemption Reserve	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	0.60	NA	0.65	NA	0.42
17	Interest Service Coverage Ratio	0.61	NA	0.65	NA	0.43

1. Net worth = Share capital + Reserves & Surplus - Deferred Tax Assets

2. Paid-up Debt Capital/ Outstanding Debt = Total Debt

3. Debt Equity Ratio = Total Debt / Net worth

4. DSCR = (Profit before interest and tax) / (Interest expense)

5. ISCR = Profit before interest and tax / Interest expense

Notes:

1. The above is an extract of the detailed format of quarter and period ended financial results filed with the Stock Exchanges in accordance with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), as amended. The full format of quarter and period ended financial results are available on the websites of the Stock exchange and the Company's website (www.ecoboxi.com).

2. For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange and the Company's website (www.ecoboxi.com).

3. The Company received the approval order dated July 17, 2025, from the Regional Director, Western Region, for the Scheme of Amalgamation under Section 233 of the Companies Act, 2013, involving the merger of Ecobx Industrials Asset II Private Limited (Transferor Company / Holding Company) with Indo Space Chittoor Private Limited (Transferee Company / Company) which is effective from November 06, 2024 (appointed date i.e. the acquisition date). The Company has completed all requisite filings with the Registrar of Companies to give effect to the scheme, in accordance with the merger order. The merger has been accounted for as a reverse acquisition in accordance with Ind AS 103 'Business Combinations', with Indo Space Chittoor II Private Limited identified as the accounting acquiree. Accordingly, comparative figures are restated to give the effect of the merger from the appointed date.

4. The above financial results of the Company are reviewed and have been approved by the Board of Directors of the Company at their respective meeting held on November 14, 2025. The Statutory Auditors have conducted limited review and have issued an unmodified report on the financial results for the quarter and period ended September 30, 2025.

For INDO SPACE CHITTOOR PRIVATE LIMITED

Ashish Shah

Director



Narayana Hrudayalaya Limited
www.narayanahealth.org
CIN:L85110KA2000PLC027497

AANCHAL ISPAT LIMITED

CIN: L27106WB1996PLC076866

Registered Office: Mouza - Charnail, NH 6, Howrah, West Bengal - 711114
Email: info@aanchalspat.com, Tel: 03212-246121, Website: www.aanchalspat.com

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2025

(Rs in Lakhs except EPS)

PARTICULARS	Quarter ended 30.09.2025	Half Year ended 30.09.2025	Quarter ended 30.09.2024	Year ended 31.03.2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations (net)	1,877.90	2,272.18	3,874.08	15,130.13
Net Profit/(Loss) for the period (Before tax Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(535.38)
Net Profit/(Loss) for the period before tax (After Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(1,790.76)
Net Profit/(Loss) for the period after tax (After Exceptional and/or Extraordinary items)	21.14	4.74	(15.35)	(1,340.23)
Total Comprehensive Income for the period after tax and Other Comprehensive Income (after tax)	21.14	4.74	(15.35)	(1,334.96)
Equity Share Capital	283.33	283.33	2,085.38	2,085.38
Other Equity (excluding Revaluation Reserve as shown in the Balance sheet of previous year)	-	-	-	(1,740.26)
Earning Per Share (Rs.10/- each)	0.75	0.17	(0.07)	(6.40)
Diluted: (in Rs)	0.75	0.17	(0.07)	(6.40)

Notes :

1 The above is an extract of the detailed format of Quarter and half year ended 30th September, 2025 unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the quarter and half year ended Financial Results are available on the BSE website: www.bseindia.com and on the Company website <http://www.aanchalspat.com/financials.html#financials>

2 The above results have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under section 133 of the Companies Act 2013 read together with the Companies (Indian Accounting Standards) Rules, 2015.



For Aanchal Ispat Limited
Sd/-
Mukesh Goel
(Managing Director)

Place : Kolkata
Date : 14.11.2025

BRAWN BIOTECH LIMITED

CIN:L74899DL1985PLC022468

REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

Extract of Standalone Un-Audited Financial Results for the quarter and half year ended 30th September 2025

(Rs. In Lakhs)

Sl. No.	Particulars	Standalone				
		Quarter Ended		Half-yearly ended		Year Ended
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	31-Mar-25
1	Total income from operation	498.22	588.86	329.81	1,087.08	736.22
2	Net Profit/(Loss) from ordinary activities after tax	7.14	23.60	(34.37)	30.74	(87.18)
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	7.14	23.60	(34.37)	30.74	(87.18)
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	7.49	26.80	(28.66)	34.30	(83.44)
5	Equity Share Capital	300.03	300.03	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year)					
7	Earning per share (before extraordinary items) (not annualised): (of rs. 10 each)					
(a)	Basic (Rs.)	0.25	0.89	-0.96	1.14	-2.78
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78
8	Earning per share (after extraordinary items) (not annualised): (of rs. 10 each)					
(a)	Basic (Rs.)	0.25	0.89	(0.96)	1.14	(2.78)
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78

NOTES :

1. The above is an extract of the detailed format of Quarterly and Half Yearly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiootech.com).

2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14-11-2025.

3. The Financials have been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ind-AS) to the extent applicable. The Company has for the first time adopted Ind-AS beginning 01st April 2017 with transition date of 01st April, 2016.

4. The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.

5. Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.



For and on behalf of Board
For Brawn Biotech Limited
Sd/-
Brij Raj Gupta
Director
DIN NO. 00974969

Place : Delhi
Date : 14-11-2025

ECOBOX INDUSTRIALS ASSET II PRIVATE LIMITED

[Now merged with INDO SPACE CHITTOOR PRIVATE LIMITED]

Corporate Identity Number: U45203MH2014PTC252644

HD-731, WeWork Vaswani Chambers, 2nd Floor, 264-265, Dr Annie Besant Rd, Municipal Colony, Worli Shivaji Nagar, Worli, Mumbai, Maharashtra 400030

Tel.: +91 9167736898 | E-mail: Compliance@ecoboxi.com | Website: www.ecoboxi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR

THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2025

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended		Six Months Ended		Year Ended
		30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	31 March 2025 (Audited)
1	Total Income from operations	477.97	-	1,031.97	-	809.69
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	-518.39	-3.50	-996.08	-3.50	-1,266.61
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	-518.39	-3.50	-996.08	-3.50	-1,266.61
6	Paid up Equity Share Capital	10.00	10.00	10.00	10.00	10.00
7	Reserves (Excluding Revaluation Reserve)	-746.84	-3.50	-746.84	-3.50	249.24
8	Securities Premium Account	-	-	-	-	-
9	Net worth	-736.84	6.50	-736.84	6.50	259.24
10	Paid up Debt Capital/ Outstanding Debt	23,906.87	-	23,906.87	-	23,354.83
11	Outstanding Redeemable Preference Shares	-	-	-	-	-
12	Debt Equity Ratio	-32.45	-1.31	-32.45	-	90.09
13	Earnings Per Share (of Rs.10/- each)-					
1. Basic	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
2. Diluted	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
14	Capital Redemption Reserve	NA	NA	NA	NA	NA
15	Debt Redemption Reserve	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	0.60	NA	0.65	NA	0.42
17	Interest Service Coverage Ratio	0.61	NA	0.65	NA	0.43

1. Net worth = Share capital + Reserves & Surplus - Deferred Tax Assets

2. Paid-up Debt Capital/ Outstanding Debt = Total Debt

3. Debt Equity Ratio = Total Debt / Net worth

4. DSCR = (Profit before interest and tax) / (Interest expense)

5. ISCR = Profit before interest and tax / Interest expense

Notes:

1. The above is an extract of the detailed format of quarter and period ended financial results filed with the Stock Exchanges in accordance with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), as amended. The full format of quarter and period ended financial results are available on the websites of the Stock exchange and the Company's website (www.ecoboxi.com).2. For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange and the Company's website (www.ecoboxi.com).

3. The Company received the approval order dated July 17, 2025, from the Regional Director, Western Region, for the Scheme of Amalgamation under Section 233 of the Companies Act, 2013, involving the merger of Ecobox Industrials Asset II Private Limited (Transferor Company / Holding Company) with Indo Space Chittoor Private Limited (Transferee Company / Company) which is effective from November 06, 2024 (appointed date i.e. the acquisition date). The Company has completed all requisite filings with the Registrar of Companies to give effect to the scheme, in accordance with the merger order. The merger has been accounted for as a reverse acquisition in accordance with Ind AS 103 'Business Combinations', with Indo Space Chittoor II Private Limited identified as the accounting acquiree. Accordingly, comparative figures are restated to give the effect of the merger from the appointed date.

4. The above financial results of the Company are reviewed and have been approved by the Board of Directors of the Company at their respective meeting held on November 14, 2025. The Statutory Auditors have conducted limited review and have issued an unmodified report on the financial results for the quarter and period ended September 30, 2025.

For INDO SPACE CHITTOOR PRIVATE LIMITED

Ashish Shah

Director

DIN : 06989999

Date : 14 Nov, 2025

Place : Mumbai

Registered Office:
No. 258/A, Bommasandra Industrial Area, Anekal Taluk,
Bengaluru- 560 099 , Karnataka, India.
Telephone: +91-8050009318
Email : investorrelations@narayanahealth.org



Narayana Hrudayalaya Limited
www.narayanahealth.org
CIN:L85110KA2000PLC027497

AANCHAL ISPAT LIMITED

CIN: L27106WB1996PLC076866

Registered Office: Mouza - Chammal, NH 6, Howrah, West Bengal - 711114
Email: info@aanchalspat.com, Tel: 03212-246121, Website: www.aanchalspat.com

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2025 (Rs in Lakhs except EPS)

PARTICULARS	Quarter ended 30.09.2025	Half Year ended 30.09.2025	Quarter ended 30.09.2024	Year ended 31.03.2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations (net)	1,877.90	2,272.18	3,874.08	15,130.13
Net Profit/(Loss) for the period (Before tax Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(535.38)
Net Profit/(Loss) for the period before tax (After Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(1,790.76)
Net Profit/(Loss) for the period after tax (After Exceptional and/or Extraordinary items)	21.14	4.74	(15.35)	(1,340.23)
Total Comprehensive Income for the period after tax and Other Comprehensive Income (after tax)	21.14	4.74	(15.35)	(1,334.96)
Equity Share Capital	283.33	283.33	2,085.38	2,085.38
Other Equity (excluding Revaluation Reserve as shown in the Balance sheet of previous year)	-	-	-	(1,740.26)
Earning Per Share (Rs.10/- each)	0.75	0.17	(0.07)	(6.40)
Diluted: (in Rs)	0.75	0.17	(0.07)	(6.40)

Notes :

- 1 The above is an extract of the detailed format of Quarter and half year ended 30th September, 2025 unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the quarter and half year ended Financial Results are available on the BSE website: www.bseindia.com and on the Company website <http://www.aanchalspat.com/financials.html#financials>
- 2 The above results have been prepared in accordance with Indian Accounting Standards ("IND AS") notified under section 133 of the Companies Act 2013 read together with the Companies (Indian Accounting Standards) Rules, 2015.



For Aanchal Ispat Limited
Sd/-
Mukesh Goel
(Managing Director)

Place : Kolkata
Date : 14.11.2025

BRAWN BIOTECH LIMITED

CIN:L74899DL1985PLC022468

REGD. OFFICE: C-64, Lajpat Nagar-I, New Delhi 110024

Extract of Standalone Un-Audited Financial Results for the quarter and half year ended 30th September 2025 (Rs. In Lakcs)

Sl. No.	Particulars	Standalone				
		Quarter Ended		Half-yearly ended		Year Ended
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	31-Mar-25
1	Total income from operation	498.22	588.86	329.81	1,087.08	736.22
2	Net Profit/(Loss) from ordinary activities after tax	7.14	23.60	(34.37)	30.74	(87.18)
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	7.14	23.60	(34.37)	30.74	(87.18)
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	7.49	26.80	(28.66)	34.30	(83.44)
5	Equity Share Capital	300.03	300.03	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year)					
7	Earning per share (before extraordinary items) (not annualised): (of rs. 10 each)					
(a)	Basic (Rs.)	0.25	0.89	-0.96	1.14	-2.78
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78
8	Earning per share (after extraordinary items) (not annualised): (of rs. 10 each)					
(a)	Basic (Rs.)	0.25	0.89	(0.96)	1.14	(2.78)
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78

- NOTES :
- The above is an extract of the detailed format of Quarterly and Half Yearly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiootech.com).
 - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14-11-2025.
 - The Financials have been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ind-AS) to the extent applicable. The Company has for the first time adopted IND-AS beginning 01st April 2017 with transition date of 01st April, 2016.
 - The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
 - Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.



For and on behalf of Board
For Brawn Biotech Limited
Sd/-
Brij Raj Gupta
Director
DIN NO. 00974969

Place : Delhi
Date : 14-11-2025

ECOBOX INDUSTRIALS ASSET II PRIVATE LIMITED

[Now merged with INDO SPACE CHITTOOR PRIVATE LIMITED]

Corporate Identity Number: U45203MH2014PTC252644

HD-731, WeWork Vaswani Chambers, 2nd Floor, 264-265, Dr Annie Besant Rd, Municipal Colony, Worli Shivaji Nagar, Worli, Mumbai, Maharashtra 400030

Tel.: +91 9167736898 | E-mail: Compliance@ecoboxi.com | Website: www.ecoboxi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2025

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended		Six Months Ended		Year Ended
		30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	31 March 2025 (Audited)
1	Total Income from operations	477.97	-	1,031.97	-	809.69
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	-518.39	-3.50	-996.08	-3.50	-1,266.61
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	-518.39	-3.50	-996.08	-3.50	-1,266.61
6	Paid up Equity Share Capital	10.00	10.00	10.00	10.00	10.00
7	Reserves (excluding Revaluation Reserve)	-746.84	-3.50	-746.84	-3.50	249.24
8	Security Premium Account	-	-	-	-	-
9	Net worth	-736.84	6.50	-736.84	6.50	259.24
10	Paid up Debt Capital/ Outstanding Debt	23,906.87	-	23,906.87	-	23,354.83
11	Outstanding Redeemable Preference Shares	-	-	-	-	-
12	Debt Equity Ratio	-32.45	-1.31	-32.45	-	90.09
13	Earnings Per Share (of Rs.10/- each)-					
1. Basic:	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
2. Diluted:	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
14	Capital Redemption Reserve	NA	NA	NA	NA	NA
15	Debt Service Coverage Ratio	NA	NA	NA	NA	NA
16	Debt Equity Ratio	0.60	NA	0.65	NA	0.42
17	Interest Service Coverage Ratio	0.61	NA	0.65	NA	0.43

1. Net worth = Share capital + Reserves & Surplus - Deferred Tax Assets

2. Paid-up Debt Capital / Outstanding Debt = Total Debt

3. Debt Equity Ratio = Total Debt / Net worth

4. DSCR = (Profit before interest and tax) / (Interest expense)

5. ISCR = Profit before interest and tax / Interest expense

Notes: 1. The above is an extract of the detailed format of quarter and period ended financial results filed with the Stock Exchanges in accordance with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), as amended. The full format of quarter and period ended financial results are available on the websites of the Stock exchange and the Company's website (www.ecoboxi.com). 2. For the other line items referred in regulation 52(4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange and the Company's website (www.ecoboxi.com). 3. The Company received the approval order dated July 17, 2025, from the Regional Director, Western Region, for the Scheme of Amalgamation under Section 233 of the Companies Act, 2013, involving the merger of Ecobox Industrials Asset II Private Limited (Transferor Company / Holding Company) with Indo Space Chittoor Private Limited (Transferee Company / Company) which is effective from November 06, 2024 (appointed date i.e. the acquisition date). The Company has completed all requisite filings with the Registrar of Companies to give effect to the scheme, in accordance with the merger order. The merger has been accounted for as a reverse acquisition in accordance with Ind AS 103 'Business Combinations', with Indo Space Chittoor II Private Limited identified as the accounting acquiree. Accordingly, comparative figures are restated to give the effect of the merger from the appointed date. 4. The above financial results of the Company are reviewed and have been approved by the Board of Directors of the Company at their respective meeting held on November 14, 2025. The Statutory Auditors have conducted limited review and have issued an unmodified report on the financial results for the quarter and period ended September 30, 2025. 5. For INDO SPACE CHITTOOR PRIVATE LIMITED Ashish Shah Director DIN : 06989999 Date : 14 Nov, 2025 Place : Mumbai6. The above is an extract of the detailed format of quarter and period ended financial results filed with the Stock Exchanges in accordance with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), as amended. The full format of the Financial Results for the quarter and half year ended 30th September, 2025 are available on the website of National Stock Exchange of India Ltd (www.nseindia.com) and BSE Ltd (www.bseindia.com) and the Company's website at <https://avrofurniture.com/financial-information.php>. The same can also be accessed by scanning the QR code provided below.

7. The above financial results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on November 14, 2025. The Statutory Auditors of the Company have conducted limited review on these results.

8. The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as notified under Section 133 of the Companies Act, 2013 read with relevant rules thereafter and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and other recognised accounting practices and policies to the extent applicable.

9. Based on the guiding principles given in Ind AS-108, "Operating Segments", the Company's business activity comprise of only one segment. Hence, no information is required to be given in respect of segment.

10. During the half year ended September 30, 2025, the Company incorporated a wholly-owned subsidiary named 'Avro Recycling Limited' on May 14, 2025. Apart from the aforesaid subsidiary, the Company did not have any other subsidiary, Joint venture, or associate company as of September 30, 2025.

11. The half yearly consolidated financial results for the half year ended 30.09.202



Narayana Hrudayalaya Limited
www.narayanahealth.org
CIN:L85110KA2000PLC027497

AANCHAL ISPAT LIMITED

CIN: L27106WB1996PLC076866

Registered Office: Mouza - Charnail, NH 6, Howrah, West Bengal - 711114
Email: info@aanchalspat.com, Tel: 03212-246121, Website: www.aanchalspat.com

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2025 (Rs in Lakhs except EPS)

PARTICULARS	Quarter ended 30.09.2025 (Unaudited)	Half Year ended 30.09.2025 (Unaudited)	Quarter ended 30.09.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Total Income from Operations (net)	1,877.90	2,272.18	3,874.08	15,130.13
Net Profit/(Loss) for the period (Before tax Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(535.38)
Net Profit/(Loss) for the period before tax (After Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(1,790.76)
Net Profit/(Loss) for the period after tax (After Exceptional and/or Extraordinary items)	21.14	4.74	(15.35)	(1,340.23)
Total Comprehensive Income for the period after tax and Other Comprehensive Income (after tax)	21.14	4.74	(15.35)	(1,334.96)
Equity Share Capital	283.33	283.33	2,085.38	2,085.38
Other Equity (excluding Revaluation Reserve as shown in the Balance sheet of previous year)	-	-	-	(1,740.26)
Earning Per Share (Rs.10/- each)	0.75	0.17	(0.07)	(6.40)
Diluted: (in Rs)	0.75	0.17	(0.07)	(6.40)

Notes :

- 1 The above is an extract of the detailed format of Quarter and half year ended 30th September, 2025 unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the quarter and half year ended Financial Results are available on the BSE website: www.bseindia.com and on the Company website <http://www.aanchalspat.com/financials.html#financials>
- 2 The above results have been prepared in accordance with Indian Accounting Standards ("IND AS") notified under section 133 of the Companies Act 2013 read together with the Companies (Indian Accounting Standards) Rules, 2015.



For Aanchal Ispat Limited
Sd/-
Mukesh Goel
(Managing Director)

Place : Kolkata
Date : 14.11.2025

BRAWN BIOTECH LIMITED

CIN:L74899DL1985PLC022468

REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

Extract of Standalone Un-Audited Financial Results for the quarter and half year ended 30th September 2025 (Rs. In Lakhs)

Sl. No.	Particulars	Standalone				
		Quarter Ended		Half-yearly ended		Year Ended
		30-Sep-25 Unaudited	30-Jun-25 Unaudited	30-Sep-24 Unaudited	30-Sep-25 Unaudited	31-Mar-25 Audited
1	Total income from operation	498.22	588.86	329.81	1,087.08	736.22
2	Net Profit/(Loss) from ordinary activities after tax	7.14	23.60	(34.37)	30.74	(87.18)
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	7.14	23.60	(34.37)	30.74	(87.18)
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	7.49	26.80	(28.66)	34.30	(83.44)
5	Equity Share Capital	300.03	300.03	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year)					
7	Earning per share (before extraordinary items) (not annualised): (of rs. 10 each)					
(a)	Basic (Rs.)	0.25	0.89	-0.96	1.14	-2.78
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78
8	Earning per share (after extraordinary items) (not annualised): (of rs. 10 each)					
(a)	Basic (Rs.)	0.25	0.89	(0.96)	1.14	(2.78)
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78

- NOTES :
- The above is an extract of the detailed format of Quarterly and Half Yearly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiootech.com).
 - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14-11-2025.
 - The Financials have been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ind-AS) to the extent applicable. The Company has for the first time adopted Ind-AS beginning 01st April 2017 with transition date of 01st April, 2016.
 - The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
 - Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.



For and on behalf of Board
For Brawn Biotech Limited
Sd/-
Brij Raj Gupta
Director
DIN NO. 00974969

Place : Delhi
Date : 14-11-2025

ECOBX INDUSTRIALS ASSET II PRIVATE LIMITED

[Now merged with INDO SPACE CHITTOOR PRIVATE LIMITED]

Corporate Identity Number: U45203MH2014PTC252644

HD-731, WeWork Vaswani Chambers, 2nd Floor, 264-265, Dr Annie Besant Rd, Municipal Colony,

Worli Shivaji Nagar, Worli, Mumbai, Maharashtra 400030

Tel.: +91 9167736898 | E-mail: Compliance@ecoboxi.com | Website: www.ecoboxi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR

THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2025

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended		Six Months Ended		Year Ended
		30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	31 March 2025 (Audited)
1	Total Income from operations	477.97	-	1,031.97	-	809.69
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	-518.39	-3.50	-996.08	-3.50	-1,266.61
5	Total Comprehensive Income for the period [Comprising Profit/Loss for the period (after tax) and Other Comprehensive Income (after tax)]	-518.39	-3.50	-996.08	-3.50	-1,266.61
6	Paid up Equity Share Capital	10.00	10.00	10.00	10.00	10.00
7	Reserves (excluding Revaluation Reserve)	-746.84	-3.50	-746.84	-3.50	249.24
8	Securities Premium Account	-	-	-	-	-
9	Net worth	-736.84	6.50	-736.84	6.50	259.24
10	Paid up Debt Capital/ Outstanding Debt	23,906.87	-	23,906.87	-	23,354.83
11	Outstanding Redeemable Preference Shares	-	-	-	-	-
12	Debt Equity Ratio	-32.45	-1.31	-32.45	-	90.09
13	Earnings Per Share (Rs.10/- each)-					
1. Basic	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
2. Diluted:	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
14	Capital Redemption Reserve	NA	NA	NA	NA	NA
15	Debt Redemption Reserve	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	0.60	NA	0.65	NA	0.42
17	Interest Service Coverage Ratio	0.61	NA	0.65	NA	0.43

1. Net worth = Share capital + Reserves & Surplus - Deferred Tax Assets

2. Paid-up Debt Capital/ Outstanding Debt = Total Debt

3. Debt Equity Ratio = Total Debt / Net worth

4. DSCR = (Profit before interest and tax) / (Interest expense)

5. ISCR = Profit before interest and tax / Interest expense

Notes: 1. The above is an extract of the detailed format of quarter and period ended financial results filed with the Stock Exchanges in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), as amended. The full format of quarter and period ended financial results are available on the websites of the Stock exchange and the Company's website (www.ecoboxi.com). 2. For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange and the Company's website (www.ecoboxi.com). 3. The Company received the approval order dated July 17, 2025, from the Regional Director, Western Region, for the Scheme of Amalgamation under Section 233 of the Companies Act, 2013, involving the merger of Ecobx Industrials Asset II Private Limited (Transferor Company / Holding Company) with Indo Space Chittoor Private Limited (Transferee Company / Company) which is effective from November 06, 2024 (appointed date i.e. the acquisition date). The Company has completed all requisite filings with the Registrar of Companies to give effect to the scheme, in accordance with the merger order. The merger has been accounted for as a reverse acquisition in accordance with Ind AS 103 'Business Combinations', with Indo Space Chittoor II Private Limited identified as the accounting acquiree. Accordingly, comparative figures are restated to give the effect of the merger from the appointed date. 4. The above financial results of the Company are reviewed and have been approved by the Board of Directors of the Company at their respective meeting held on November 14, 2025. The Statutory Auditors have conducted limited review and have issued an unmodified report on the financial results for the quarter and period ended September 30, 2025. For INDO SPACE CHITTOOR PRIVATE LIMITED

Ashish Shah

Director

DIN : 06989999

Date : 14 Nov, 2025

Place : Mumbai

Registered Office:
No. 258/A, Bommasandra Industrial Area, Anekal Taluk,
Bengaluru- 560 099 , Karnataka, India.
Telephone: +91-8050009318
Email : investorrelations@narayanahealth.org

Narayana Hrudayalaya Limited

www.narayanahealth.org

CIN:L85110KA2000PLC027497

EXTRACT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2025

(₹ in Million, except per share data)

Sl. No.	Particulars	Standalone				Consolidated			
Quarter ended 30.09.2025 Un-audited	Quarter ended 30.09.2024 Un-audited	Half Year							



Narayana Hrudayalaya Limited
www.narayanahealth.org
CIN:L85110KA2000PLC027497

AANCHAL ISPAT LIMITED

CIN: L27106WB1996PLC076866

Registered Office: Mouza - Charnail, NH 6, Howrah, West Bengal - 711114
Email: info@aanchalspat.com, Tel: 03212-246121, Website: www.aanchalspat.com

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2025

(Rs in Lakhs except EPS)

PARTICULARS	Quarter ended 30.09.2025	Half Year ended 30.09.2025	Quarter ended 30.09.2024	Year ended 31.03.2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations (net)	1,877.90	2,272.18	3,874.08	15,130.13
Net Profit/(Loss) for the period (Before tax Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(535.38)
Net Profit/(Loss) for the period before tax (After Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(1,790.76)
Net Profit/(Loss) for the period after tax (After Exceptional and/or Extraordinary items)	21.14	4.74	(15.35)	(1,340.23)
Total Comprehensive Income for the period after tax and Other Comprehensive Income (after tax)	21.14	4.74	(15.35)	(1,334.96)
Equity Share Capital	283.33	283.33	2,085.38	2,085.38
Other Equity (excluding Revaluation Reserve as shown in the Balance sheet of previous year)	-	-	-	(1,740.26)
Earning Per Share (Rs.10/- each)	0.75	0.17	(0.07)	(6.40)
Diluted: (in Rs)	0.75	0.17	(0.07)	(6.40)

Notes :

1 The above is an extract of the detailed format of Quarter and half year ended 30th September, 2025 unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the quarter and half year ended Financial Results are available on the BSE website: www.bseindia.com and on the Company website <http://www.aanchalspat.com/financials.html#financials>

2 The above results have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under section 133 of the Companies Act 2013 read together with the Companies (Indian Accounting Standards) Rules, 2015.



For Aanchal Ispat Limited
Sd/-
Mukesh Goel
(Managing Director)

Place : Kolkata
Date : 14.11.2025

BRAWN BIOTECH LIMITED

CIN:L74899DL1985PLC022468

REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

Extract of Standalone Un-Audited Financial Results for the quarter and half year ended 30th September 2025

(Rs. In Lakhs)

Sl. No.	Particulars	Standalone				
		Quarter Ended		Half-yearly ended		Year Ended
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	31-Mar-25
1	Total income from operation	498.22	588.86	329.81	1,087.08	736.22
2	Net Profit/(Loss) from ordinary activities after tax	7.14	23.60	(34.37)	30.74	(87.18)
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	7.14	23.60	(34.37)	30.74	(87.18)
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	7.49	26.80	(28.66)	34.30	(83.44)
5	Equity Share Capital	300.03	300.03	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year)					
7	Earning per share (before extraordinary items) (not annualised): (of rs. 10 each)					
(a)	Basic (Rs.)	0.25	0.89	-0.96	1.14	-2.78
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78
8	Earning per share (after extraordinary items) (not annualised): (of rs. 10 each)					
(a)	Basic (Rs.)	0.25	0.89	(0.96)	1.14	(2.78)
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78

NOTES :

1. The above is an extract of the detailed format of Quarterly and Half Yearly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiootech.com).

2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14-11-2025.

3. The Financials have been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ind-AS) to the extent applicable. The Company has for the first time adopted Ind-AS beginning 01st April 2017 with transition date of 01st April, 2016.

4. The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.

5. Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.



For and on behalf of Board
For Brawn Biotech Limited
Sd/-
Brij Raj Gupta
Director
DIN NO. 00974969

Place : Delhi
Date : 14-11-2025

ECOBX INDUSTRIALS ASSET II PRIVATE LIMITED

[Now merged with INDO SPACE CHITTOOR PRIVATE LIMITED]

Corporate Identity Number: U45203MH2014PTC252644

HD-731, WeWork Vaswani Chambers, 2nd Floor, 264-265, Dr Annie Besant Rd, Municipal Colony, Worli Shivaji Nagar, Worli, Mumbai, Maharashtra 400030

Tel.: +91 9167736898 | E-mail: Compliance@ecoboxi.com | Website: www.ecoboxi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR

THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2025

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended		Six Months Ended		Year Ended
		30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	31 March 2025 (Audited)
1	Total Income from operations	477.97	-	1,031.97	-	809.69
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	-518.39	-3.50	-996.08	-3.50	-1,266.61
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	-518.39	-3.50	-996.08	-3.50	-1,266.61
6	Paid up Equity Share Capital	10.00	10.00	10.00	10.00	10.00
7	Reserves (Excluding Revaluation Reserve)	-746.84	-3.50	-746.84	-3.50	249.24
8	Securities Premium Account	-	-	-	-	-
9	Net worth	-736.84	6.50	-736.84	6.50	259.24
10	Paid up Debt Capital/ Outstanding Debt	23,906.87	-	23,906.87	-	23,354.83
11	Outstanding Redeemable Preference Shares	-	-	-	-	-
12	Debt Equity Ratio	-32.45	-1.31	-32.45	-	90.09
13	Earnings Per Share (of Rs.10/- each)-					
1. Basic	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
2. Diluted	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
14	Capital Redemption Reserve	NA	NA	NA	NA	NA
15	Debt Redemption Reserve	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	0.60	NA	0.65	NA	0.42
17	Interest Service Coverage Ratio	0.61	NA	0.65	NA	0.43

1. Net worth = Share capital + Reserves & Surplus - Deferred Tax Assets

2. Paid-up Debt Capital/ Outstanding Debt = Total Debt

3. Debt Equity Ratio = Total Debt / Net worth

4. DSCR = (Profit before interest and tax) / (Interest expense)

5. ISCR = Profit before interest and tax / Interest expense

Notes:

1. The above is an extract of the detailed format of quarter and period ended financial results filed with the Stock Exchanges in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), as amended. The full format of quarter and period ended financial results are available on the websites of the Stock exchange and the Company's website (www.ecoboxi.com).2. For the other line items referred in regulation 52 (4) of LODR Regulations, pertinent disclosures have been made to the Stock Exchange and the Company's website (www.ecoboxi.com).

3. The Company received the approval order dated July 17, 2025, from the Regional Director, Western Region, for the Scheme of Amalgamation under Section 233 of the Companies Act, 2013, involving the merger of Ecobx Industrials Asset II Private Limited (Transferor Company / Holding Company) with Indo Space Chittoor Private Limited (Transferee Company / Company) which is effective from November 06, 2024 (appointed date i.e. the acquisition date). The Company has completed all requisite filings with the Registrar of Companies to give effect to the scheme, in accordance with the merger order. The merger has been accounted for as a reverse acquisition in accordance with Ind AS 103 'Business Combinations', with Indo Space Chittoor II Private Limited identified as the accounting acquiree. Accordingly, comparative figures are restated to give the effect of the merger from the appointed date.

4. The above financial results of the Company are reviewed and have been approved by the Board of Directors of the Company at their respective meeting held on November 14, 2025. The Statutory Auditors have conducted limited review and have issued an unmodified report on the financial results for the quarter and period ended September 30, 2025.

For INDO SPACE CHITTOOR PRIVATE LIMITED

Ashish Shah

Director

DIN : 06989999

Date : 14 Nov, 2025

Place : Mumbai

Registered Office:
No. 258/A, Bommasandra Industrial Area, Anekal Taluk,
Bengaluru- 560 099 , Karnataka, India.
Telephone: +91-8050009318
Email : investorrelations@narayanahealth.org

Nar



Narayana Hrudayalaya Limited
www.narayanahealth.org
CIN:L85110KA2000PLC027497

AANCHAL ISPAT LIMITED

CIN: L27106WB1996PLC076866

Registered Office: Mouza - Chamrai, NH 6, Howrah, West Bengal - 711114
Email: info@aanchalspat.com, Tel: 03212-246121, Website: www.aanchalspat.com

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2025

(Rs in Lakhs except EPS)

PARTICULARS	Quarter ended 30.09.2025	Half Year ended 30.09.2025	Quarter ended 30.09.2024	Year ended 31.03.2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations (net)	1,877.90	2,272.18	3,874.08	15,130.13
Net Profit/(Loss) for the period (Before tax Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(535.38)
Net Profit/(Loss) for the period before tax (After Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(1,790.76)
Net Profit/(Loss) for the period after tax (After Exceptional and/or Extraordinary items)	21.14	4.74	(15.35)	(1,340.23)
Total Comprehensive Income for the period after tax and Other Comprehensive Income (after tax)	21.14	4.74	(15.35)	(1,334.96)
Equity Share Capital	283.33	283.33	2,085.38	2,085.38
Other Equity (excluding Revaluation Reserve as shown in the Balance sheet of previous year)	-	-	-	(1,740.26)
Earning Per Share (Rs.10/- each)	0.75	0.17	(0.07)	(6.40)
Diluted: (in Rs)	0.75	0.17	(0.07)	(6.40)

Notes :

- The above is an extract of the detailed format of Quarter and half year ended 30th September, 2025 unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the quarter and half year ended Financial Results are available on the BSE website- www.bseindia.com and on the Company website <http://www.aanchalspat.com/financials.html#financials>
- The above results have been prepared in accordance with Indian Accounting Standards ("IND AS") notified under section 133 of the Companies Act 2013 read together with the Companies (Indian Accounting Standards) Rules, 2015.



For Aanchal Ispat Limited
Sd/-
Mukesh Goel
(Managing Director)

Place : Kolkata
Date : 14.11.2025

BRAWN BIOTECH LIMITED

CIN:L74899DL1985PLC022468

REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

Extract of Standalone Un-Audited Financial Results for the quarter and half year ended 30th September 2025

(Rs. In Lacs)

Sl. No.	Particulars	Standalone					
		Quarter Ended		Half-yearly ended		Year Ended	
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	30-Sep-24	31-Mar-25
1	Total income from operation	498.22	588.86	329.81	1,087.08	736.22	1,355.83
2	Net Profit/(Loss) from ordinary activities after tax	7.14	23.60	(34.37)	30.74	(87.18)	(179.81)
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	7.14	23.60	(34.37)	30.74	(87.18)	(179.81)
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	7.49	26.80	(28.66)	34.30	(83.44)	(176.08)
5	Equity Share Capital	300.03	300.03	300.03	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year)						
7	Earning per share (before extraordinary items) (not annualised): (of rs. 10 each)						
(a)	Basic (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87
8	Earning per share (after extraordinary items) (not annualised): (of rs. 10 each)						
(a)	Basic (Rs.)	0.25	0.89	(0.96)	1.14	(2.78)	(5.87)
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87

- NOTES :
- The above is an extract of the detailed format of Quarterly and Half Yearly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiotech.com).
 - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14-11-2025.
 - The Financials have been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ind-AS) to the extent applicable. The Company has for the first time adopted IND-AS beginning 01st April 2017 with transition date of 01st April, 2016.
 - The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
 - Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.



For and on behalf of Board
For Brawn Biotech Limited
Sd/-
Brij Raj Gupta
Director
DIN NO. 00974969

Place : Delhi
Date : 14-11-2025

ECOBX INDUSTRIALS ASSET II PRIVATE LIMITED

[Now merged with INDO SPACE CHITTOOR PRIVATE LIMITED]

Corporate Identity Number: U45203MH2014PTC252644

HD-731, WeWork Vaswani Chambers, 2nd Floor, 264-265, Dr Annie Besant Rd, Municipal Colony, Worli Shivaji Nagar, Worli, Mumbai, Maharashtra 400030

Tel.: +91 9167736898 | E-mail: Compliance@ecoboxi.com | Website: www.ecoboxi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2025

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended		Six Months Ended		Year Ended
		30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	31 March 2025 (Audited)
1	Total Income from operations	477.97	-	1,031.97	-	809.69
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	-518.39	-3.50	-996.08	-3.50	-1,266.61
5	Total Comprehensive Income for the period (Comprising Profit/Loss) for the period (after tax) and Other Comprehensive Income (after tax)	-518.39	-3.50	-996.08	-3.50	-1,266.61
6	Paid-up Equity Share Capital	10.00	10.00	10.00	10.00	10.00
7	Reserves (excluding Revaluation Reserve)	-746.84	-3.50	-746.84	-3.50	249.24
8	Securities Premium Account	-	-	-	-	-
9	Net worth	-736.84	6.50	-736.84	6.50	259.24
10	Paid up Debt Capital/ Outstanding Debt	23,906.87	-	23,906.87	-	23,354.83
11	Outstanding Redeemable Preference Shares	-	-	-	-	-
12	Debt Equity Ratio	-32.45	-1.31	-32.45	-	90.09
13	Earnings Per Share (of Rs.10/- each)-					
1. Basic:	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
2. Diluted:	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
14	Capital Redemption Reserve	NA	NA	NA	NA	NA
15	Debenture Redemption Reserve	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	0.60	NA	0.65	NA	0.42
17	Interest Service Coverage Ratio	0.61	NA	0.65	NA	0.43

1. Net worth = Share capital + Reserves & Surplus - Deferred Tax Assets

2. Paid-up Debt Capital/ Outstanding Debt = Total Debt

3. Debt Equity Ratio = Total Debt / Net worth

4. DSCR = (Profit before interest and tax) / (Interest expense)

5. ISCR = Profit before interest and tax / Interest expense

- Notes:
- The above is an extract of the detailed format of quarter and period ended financial results filed with the Stock Exchanges in accordance with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), as amended. The full format of quarter and period ended financial results are available on the websites of the Stock exchange and the Company's website (www.ecoboxi.com).
 - For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange and the Company's website (www.ecoboxi.com).
 - The Company received the approval order dated July 17, 2025, from the Regional Director, Western Region, for the Scheme of Amalgamation under Section 233 of the Companies Act, 2013, involving the merger of Ecobx Industrials Asset II Private Limited (Transferor Company / Holding Company) with Indo Space Chittoor Private Limited (Transferee Company / Company) which is effective from November 06, 2024 (appointed date i.e. the acquisition date). The Company has completed all requisite filings with the Registrar of Companies to give effect to the scheme, in accordance with the merger order. The merger has been accounted for as a reverse acquisition in accordance with Ind AS 103 'Business Combinations', with Indo Space Chittoor II Private Limited identified as the accounting acquiree. Accordingly, comparative figures are restated to give the effect of the merger from the appointed date.
 - The above financial results of the Company are reviewed and have been approved by the Board of Directors of the Company at their respective meeting held on November 14, 2025. The Statutory Auditors have conducted limited review and have issued an unmodified report on the financial results for the quarter and period ended September 30, 2025.

For INDO SPACE CHITTOOR PRIVATE LIMITED

Ashish Shah

Director

DIN : 06898999

Date : 14 Nov, 2025

Place : Mumbai



Registered Office:
No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru- 560 099 , Karnataka, India.
Telephone: +91-80500093



Narayana Hrudayalaya Limited
www.narayanahealth.org
CIN:L85110KA2000PLC027497

AANCHAL ISPAT LIMITED

CIN: L27106WB1996PLC076866

Registered Office: Mouza - Chamrai, NH 6, Howrah, West Bengal - 711114
Email: info@aanchalispat.com, Tel: 03212-246121, Website: www.aanchalispat.com

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2025

(Rs in Lakhs except EPS)

PARTICULARS	Quarter ended 30.09.2025	Half Year ended 30.09.2025	Quarter ended 30.09.2024	Year ended 31.03.2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations (net)	1,877.90	2,272.18	3,874.08	15,130.13
Net Profit/(Loss) for the period (Before tax Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(535.38)
Net Profit/(Loss) for the period before tax (After Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(1,790.76)
Net Profit/(Loss) for the period after tax (After Exceptional and/or Extraordinary items)	21.14	4.74	(15.35)	(1,340.23)
Total Comprehensive Income for the period after tax and Other Comprehensive Income (after tax)	21.14	4.74	(15.35)	(1,334.96)
Equity Share Capital	283.33	283.33	2,085.38	2,085.38
Other Equity (excluding Revaluation Reserve as shown in the Balance sheet of previous year)	-	-	-	(1,740.26)
Earning Per Share (Rs.10/- each)	0.75	0.17	(0.07)	(6.40)
Diluted: (in Rs)	0.75	0.17	(0.07)	(6.40)

Notes :
1. The above is an extract of the detailed format of Quarter and half year ended 30th September, 2025 unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the quarter and half year ended Financial Results are available on the BSE website: www.bseindia.com and on the Company website <http://www.aanchalispat.com/financials.html#financials>

2. The above results have been prepared in accordance with Indian Accounting Standards ("IND AS") notified under section 133 of the Companies Act 2013 read together with the Companies (Indian Accounting Standards) Rules, 2015.



For Aanchal Ispat Limited
Sd/-
Mukesh Goel
(Managing Director)

Place : Kolkata
Date : 14.11.2025

BRAWN BIOTECH LIMITED

CIN:L74899DL1985PLC022468

REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

Extract of Standalone Un-Audited Financial Results for the quarter and half year ended 30th September 2025

(Rs. In Lacs)

Sl. No.	Particulars	Standalone					
		Quarter Ended		Half-yearly ended		Year Ended	
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	30-Sep-24	31-Mar-25
1	Total income from operation	498.22	588.86	329.81	1,087.08	736.22	1,355.83
2	Net Profit/(Loss) from ordinary activities after tax	7.14	23.60	(34.37)	30.74	(87.18)	(179.81)
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	7.14	23.60	(34.37)	30.74	(87.18)	(179.81)
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	7.49	26.80	(28.66)	34.30	(83.44)	(176.08)
5	Equity Share Capital	300.03	300.03	300.03	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year						
7	Earning per share (before extraordinary items) (not annualised): (of rs. 10 each)						
(a)	Basic (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87
8	Earning per share (after extraordinary items) (not annualised): (of rs. 10 each)						
(a)	Basic (Rs.)	0.25	0.89	(0.96)	1.14	(2.78)	(5.87)
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87

NOTES :
1. The above is an extract of the detailed format of Quarterly and Half Yearly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiotech.com).
2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14-11-2025.
3. The Financials have been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ind-AS) to the extent applicable. The Company has for the first time adopted IND-AS beginning 01st April 2017 with transition date of 01st April, 2016.
4. The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
5. Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.



For and on behalf of Board
For Brawn Biotech Limited
Sd/-
Brij Raj Gupta
Director
DIN NO. 00974969

Place : Delhi
Date : 14-11-2025

ECOBX INDUSTRIALS ASSET II PRIVATE LIMITED

[Now merged with INDO SPACE CHITTOOR PRIVATE LIMITED]

Corporate Identity Number: U45203MH2014PTC252644

HD-731, WeWork Vaswani Chambers, 2nd Floor, 264-265, Dr Annie Besant Rd, Municipal Colony, Worli Shivaji Nagar, Worli, Mumbai, Maharashtra 400030

Tel.: +91 9167736898 | E-mail: Compliance@ecoboxi.com | Website: www.ecoboxi.com**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2025**

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended		Six Months Ended		Year Ended
		30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	31 March 2025 (Audited)
1	Total Income from operations	477.97	-	1,031.97	-	809.69
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	-518.39	-3.50	-996.08	-3.50	-1,266.61
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	-518.39	-3.50	-996.08	-3.50	-1,266.61
6	Paid-up Equity Share Capital	10.00	10.00	10.00	10.00	10.00
7	Reserves (excluding Revaluation Reserve)	-746.84	-3.50	-746.84	-3.50	249.24
8	Securities Premium Account	-	-	-	-	-
9	Net worth	-736.84	6.50	-736.84	6.50	259.24
10	Paid up Debt Capital/ Outstanding Debt	23,906.87	-	23,906.87	-	23,354.83
11	Outstanding Redeemable Preference Shares	-	-	-	-	-
12	Debt Equity Ratio	-32.45	-1.31	-32.45	-	90.09
13	Earnings Per Share (of Rs.10/- each):					
1. Basic:	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
2. Diluted:	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
14	Capital Redemption Reserve	NA	NA	NA	NA	NA
15	Debenture Redemption Reserve	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	0.60	NA	0.65	NA	0.42
17	Interest Service Coverage Ratio	0.61	NA	0.65	NA	0.43

1. Net worth = Share capital + Reserves & Surplus - Deferred Tax Assets

2. Paid-up Debt Capital / Outstanding Debt = Total Debt

3. Debt Equity Ratio = Total Debt / Net worth

4. DSCR = (Profit before interest and tax) / (Interest expense)

5. ISCR = Profit before interest and tax / Interest expense

Notes:
1. The above is an extract of the detailed format of quarter and period ended financial results filed with the Stock Exchanges in accordance with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), as amended. The full format of quarter and period ended financial results are available on the websites of the Stock exchange and the Company's website (www.ecoboxi.com).
2. For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange and the Company's website (www.ecoboxi.com).

3. The Company received the approval order dated July 17, 2025, from the Regional Director, Western Region, for the Scheme of Amalgamation under Section 233 of the Companies Act, 2013, involving the merger of Ecobx Industrials Asset II Private Limited (Transferor Company / Holding Company) with Indo Space Chittoor Private Limited (Transferee Company / Company) which is effective from November 06, 2024 (appointed date i.e. the acquisition date). The Company has completed all requisite filings with the Registrar of Companies to give effect to the scheme, in accordance with the merger order. The merger has been accounted for as a reverse acquisition in accordance with Ind AS 103 'Business Combinations', with Indo Space Chittoor II Private Limited identified as the accounting acquiree. Accordingly, comparative figures are restated to give the effect of the merger from the appointed date.

4. The above financial results of the Company are reviewed and have been approved by the Board of Directors of the Company at their respective meeting held on November 14, 2025. The Statutory Auditors have conducted limited review and have issued an unmodified report on the financial results for the quarter and period ended September 30, 2025.

For INDO SPACE CHITTOOR PRIVATE LIMITED

Ashish Shah

Director

DIN : 06898999

Date : 14 Nov, 2025

Place : Mumbai

Notes:

1. The above is an extract of the detailed format of quarter and period ended financial results filed with the Stock Exchanges in accordance with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), as amended. The full format of the Financial Results for the quarter and half year ended 30th September, 2025 are available on the website of National Stock Exchange of India Ltd (www.nseindia.com) and BSE Ltd (www.bseindia.com) and the Company's website



Narayana Hrudayalaya Limited
www.narayanahealth.org
CIN:L85110KA2000PLC027497

AANCHAL ISPAT LIMITED

CIN: L27106WB1996PLC076866

Registered Office: Mouza - Charnail, NH 6, Howrah, West Bengal - 711114
Email: info@aanchalspat.com, Tel: 03212-246121, Website: www.aanchalspat.com

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2025 (Rs in Lakhs except EPS)

PARTICULARS	Quarter ended 30.09.2025	Half Year ended 30.09.2025	Quarter ended 30.09.2024	Year ended 31.03.2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations (net)	1,877.90	2,272.18	3,874.08	15,130.13
Net Profit/(Loss) for the period (Before tax Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(535.38)
Net Profit/(Loss) for the period before tax (After Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(1,790.76)
Net Profit/(Loss) for the period after tax (After Exceptional and/or Extraordinary items)	21.14	4.74	(15.35)	(1,340.23)
Total Comprehensive Income for the period after tax and Other Comprehensive Income (after tax)	21.14	4.74	(15.35)	(1,334.96)
Equity Share Capital	283.33	283.33	2,085.38	2,085.38
Other Equity (excluding Revaluation Reserve as shown in the Balance sheet of previous year)	-	-	-	(1,740.26)
Earning Per Share (Rs.10/- each)	0.75	0.17	(0.07)	(6.40)
Diluted: (in Rs)	0.75	0.17	(0.07)	(6.40)

Notes :

- 1 The above is an extract of the detailed format of Quarter and half year ended 30th September, 2025 unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the quarter and half year ended Financial Results are available on the BSE website: www.bseindia.com and on the Company website <http://www.aanchalspat.com/financials.html#financials>
- 2 The above results have been prepared in accordance with Indian Accounting Standards ("IND AS") notified under section 133 of the Companies Act 2013 read together with the Companies (Indian Accounting Standards) Rules, 2015.



For Aanchal Ispat Limited
Sd/-
Mukesh Goel
(Managing Director)

Place : Kolkata
Date : 14.11.2025

BRAWN BIOTECH LIMITED

CIN:L74899DL1985PLC022468

REGD. OFFICE: C-64, Lajpat Nagar-I, New Delhi 110024

Extract of Standalone Un-Audited Financial Results for the quarter and half year ended 30th September 2025 (Rs. In Lakcs)

Sl. No.	Particulars	Standalone				
		Quarter Ended		Half-yearly ended		Year Ended
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	31-Mar-25
1	Total income from operation	498.22	588.86	329.81	1,087.08	736.22
2	Net Profit/(Loss) from ordinary activities after tax	7.14	23.60	(34.37)	30.74	(87.18)
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	7.14	23.60	(34.37)	30.74	(87.18)
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	7.49	26.80	(28.66)	34.30	(83.44)
5	Equity Share Capital	300.03	300.03	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year)					
7	Earning per share (before extraordinary items) (not annualised): (of rs. 10 each)					
(a)	Basic (Rs.)	0.25	0.89	-0.96	1.14	-2.78
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78
8	Earning per share (after extraordinary items) (not annualised): (of rs. 10 each)					
(a)	Basic (Rs.)	0.25	0.89	(0.96)	1.14	(2.78)
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78

- NOTES :
- The above is an extract of the detailed format of Quarterly and Half Yearly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half yearly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiootech.com).
 - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14-11-2025.
 - The Financials have been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ind-AS) to the extent applicable. The Company has for the first time adopted IND-AS beginning 01st April 2017 with transition date of 01st April, 2016.
 - The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
 - Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.



For and on behalf of Board
For Brawn Biotech Limited
Sd/-
Brij Raj Gupta
Director
DIN NO. 00974969

Place : Delhi
Date : 14-11-2025

ECOBOX INDUSTRIALS ASSET II PRIVATE LIMITED

[Now merged with INDO SPACE CHITTOOR PRIVATE LIMITED]

Corporate Identity Number: U45203MH2014PTC252644

HD-731, WeWork Vaswani Chambers, 2nd Floor, 264-265, Dr Annie Besant Rd, Municipal Colony, Worli Shivaji Nagar, Worli, Mumbai, Maharashtra 400030

Tel.: +91 9167736898 | E-mail: Compliance@ecoboxi.com | Website: www.ecoboxi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR

THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2025

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended		Six Months Ended		Year Ended
		30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	31 March 2025 (Audited)
1	Total Income from operations	477.97	-	1,031.97	-	809.69
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	-518.39	-3.50	-996.08	-3.50	-1,266.61
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	-518.39	-3.50	-996.08	-3.50	-1,266.61
6	Paid up Equity Share Capital	10.00	10.00	10.00	10.00	10.00
7	Reserves (excluding Revaluation Reserve)	-746.84	-3.50	-746.84	-3.50	249.24
8	Securities Premium Account	-	-	-	-	-
9	Net worth	-736.84	6.50	-736.84	6.50	259.24
10	Paid up Debt Capital/ Outstanding Debt	23,906.87	-	23,906.87	-	23,354.83
11	Outstanding Redeemable Preference Shares	-	-	-	-	-
12	Debt Equity Ratio	-32.45	-1.31	-32.45	-	90.09
13	Earnings Per Share (of Rs.10/- each)-					
1. Basic	-518.39	-2,160.89	-996.08	-2,160.89	-	-1,266.61
2. Diluted:	-518.39	-2,160.89	-996.08	-2,160.89	-	-1,266.61
14	Capital Redemption Reserve	NA	NA	NA	NA	NA
15	Debt Service Coverage Ratio	NA	NA	NA	NA	NA
16	Debt Equity Ratio	0.60	NA	0.65	NA	0.42
17	Interest Service Coverage Ratio	0.61	NA	0.65	NA	0.43

1. Net worth = Share capital + Reserves & Surplus – Deferred Tax Assets

2. Paid-up Debt Capital / Outstanding Debt = Total Debt

3. Debt Equity Ratio = Total Debt / Net worth

4. DSCR = (Profit before interest and tax) / (Interest expense)

5. ISCR = Profit before interest and tax / Interest expense

Notes: 1. The above is an extract of the detailed format of quarter and period ended financial results filed with the Stock Exchanges in accordance with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), as amended. The full format of quarter and period ended financial results are available on the websites of the Stock exchange and the Company's website (www.ecoboxi.com). 2. For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange and the Company's website (www.ecoboxi.com). 3. The Company received the approval order dated July 17, 2025, from the Regional Director, Western Region, for the Scheme of Amalgamation under Section 233 of the Companies Act, 2013, involving the merger of Ecobox Industrials Asset II Private Limited (Transferor Company / Holding Company) with Indo Space Chittoor Private Limited (Transferee Company / Company) which is effective from November 06, 2024 (appointed date i.e. the acquisition date). The Company has completed all requisite filings with the Registrar of Companies to give effect to the scheme, in accordance with the merger order. The merger has been accounted for as a reverse acquisition in accordance with Ind AS 103 'Business Combinations', with Indo Space Chittoor II Private Limited identified as the accounting acquiree. Accordingly, comparative figures are restated to give the effect of the merger from the appointed date.

4. The above financial results of the Company are reviewed and have been approved by the Board of Directors of the Company at their respective meeting held on November 14, 2025. The Statutory Auditors have conducted limited review and have issued an unmodified report on the financial results for the quarter and period ended September 30, 2025.

For INDO SPACE CHITTOOR PRIVATE LIMITED

Ashish Shah
Director
DIN : 06989999
Date : 14 Nov, 2025
Place : Mumbai

Registered Office:
No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru- 560 099 , Karnataka, India.
Telephone: +91-8050009318
Email : investorrelations@narayanahealth.org

Narayana Hrudayalaya Limited
www.narayanahealth.org
CIN:L85110KA2000PLC027497

EXTRACT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2025

(\$ in Million, except per share data)

Sl. No.	Particulars	Standalone				Consolidated			
Quarter ended 30.09.2025	Quarter ended 30.09.2024	Half Year ended 30.09.2025	Year ended 31.03.2025	Quarter ended 30.09.2025	Quarter ended 30.09.2024	Half Year ended 30.09.2025	Year ended 31.03.2025		
Un-audited	Un-audited</th								

AANCHAL ISPAT LIMITED

CIN: L27106WB1996PLC076866

Registered Office: Mouza - Chamrall, NH 6, Howrah, West Bengal - 711114
 Email: info@aanchalispat.com, Tel: 03212-246121, Website: www.aanchalispat.com

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2025

(Rs in Lakhs except EPS)

PARTICULARS	Quarter ended 30.09.2025	Half Year ended 30.09.2025	Quarter ended 30.09.2024	Year ended 31.03.2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations (net)	1,877.90	2,272.18	3,874.08	15,130.13
Net Profit/(Loss) for the period (Before tax Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(535.38)
Net Profit/(Loss) for the period before tax (After Exceptional and/or Extraordinary items)	20.16	5.72	(15.58)	(1,790.76)
Net Profit/(Loss) for the period after tax (After Exceptional and/or Extraordinary items)	21.14	4.74	(15.35)	(1,340.23)
Total Comprehensive Income for the period after tax and Other Comprehensive Income (after tax)	21.14	4.74	(15.35)	(1,334.96)
Equity Share Capital	283.33	283.33	2,085.38	2,085.38
Other Equity (excluding Revaluation Reserve as shown in the Balance sheet of previous year)	-	-	-	(1,740.26)
Earnings Per Share (Rs.10/- each)	0.75	0.17	(0.07)	(6.40)
Diluted: (in Rs)	0.75	0.17	(0.07)	(6.40)

Notes :

- The above is an extract of the detailed format of Quarter and half year ended 30th September, 2025 unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the quarter and half year ended Financial Results are available on the BSE website: www.bseindia.com and on the Company website <http://www.aanchalispat.com/financials.html#financials>
- The above results have been prepared in accordance with Indian Accounting Standards ("IND AS") notified under section 133 of the Companies Act 2013 read together with the Companies (Indian Accounting Standards) Rules, 2015.



For Aanchal Ispat Limited
Sd/-
Mukesh Goel
(Managing Director)

Place : Kolkata
Date : 14-11-2025

BRAWN BIOTECH LIMITED

CIN:L74899DL1985PLC022468

REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

Extract of Standalone Un-Audited Financial Results for the quarter and half year ended 30th September 2025

(Rs. In Lakhs)

Sl. No.	Particulars	Standalone					
		Quarter Ended		Half-yearly ended		Year Ended	
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	30-Sep-24	31-Mar-25
1	Total Income from operation	498.22	588.86	329.81	1,087.08	736.22	1,355.83
2	Net Profit/(Loss) from ordinary activities after tax	7.14	23.60	(34.37)	30.74	(87.18)	(179.81)
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	7.14	23.60	(34.37)	30.74	(87.18)	(179.81)
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	7.49	26.80	(28.66)	34.30	(83.44)	(176.08)
5	Equity Share Capital	300.03	300.03	300.03	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year)						
7	Earning per share (before extraordinary items) (not annualised): (of rs. 10 each)						
(a)	Basic (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87
8	Earning per share (after extraordinary items) (not annualised): (of rs. 10 each)						
(a)	Basic (Rs.)	0.25	0.89	(0.96)	1.14	(2.78)	(5.87)
(b)	Diluted (Rs.)	0.25	0.89	-0.96	1.14	-2.78	-5.87

- NOTES :
- The above is an extract of the detailed format of Quarterly and Half Yearly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbio.com).
 - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14-11-2025.
 - The Financials have been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ind-AS) to the extent applicable. The Company has for the first time adopted IND-AS beginning 01st April 2017 with transition date of 01st April, 2016.
 - The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
 - Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.



For and on behalf of Board
For Brown Biotech Limited
Sd/-
Brij Raj Gupta
Director
DIN NO. 00574969

Place : Delhi
Date : 14-11-2025

ECOBX INDUSTRIALS ASSET II PRIVATE LIMITED

[Now merged with INDO SPACE CHITTOOR PRIVATE LIMITED]

Corporate Identity Number: U45203MH2014PTC252644

HD-731, WeWork Vaswani Chambers, 2nd Floor, 264-265, Dr Annie Besant Rd, Municipal Colony,

World Shivaji Nagar, Worli, Mumbai, Maharashtra 400039

Tel: +91 9167736898 | E-mail: Compliance@ecoboxi.com | Website: www.ecoboxi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2025

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended		Six Months Ended		Year Ended
		30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	
1	Total Income from operations	477.97	-	1,031.97	-	809.69
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	-619.62	-4.67	-1,190.60	-4.67	-1,228.81
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	-518.39	-3.50	-996.08	-3.50	-1,266.61
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	-518.39	-3.50	-996.08	-3.50	-1,266.61
6	Paid up Equity Share Capital	10.00	10.00	10.00	10.00	10.00
7	Reserves (excluding Revaluation Reserve)	-746.84	-3.50	-746.84	-3.50	249.24
8	Securities Premium Account	-	-	-	-	-
9	Net worth	736.84	6.50	736.84	6.50	259.24
10	Paid up Debt Capital/ Outstanding Debt	23,906.87	-	23,906.87	-	23,354.83
11	Outstanding Redeemable Preference Shares	-	-	-	-	-
12	Debt Equity Ratio	-32.45	-1.31	-32.45	-	90.09
13	Earnings Per Share (of Rs.10/- each)-					
1. Basic	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
2. Diluted	-518.39	-2,160.89	-996.08	-2,160.89	-1,266.61	
14	Capital Redemption Reserve	NA	NA	NA	NA	NA
15	Debt Redemption Reserve	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	0.60	NA	0.65	NA	0.42
17	Interest Service Coverage Ratio	0.61	NA	0.65	NA	0.43

1. Net worth = Share capital + Reserves & Surplus - Deferred Tax Assets

2. Paid-up Capital / Outstanding Debt = Total Debt

3. Debt Equity Ratio = Total Debt / Net worth

4. DSCR = (Profit before interest and tax) / (Interest expense)

5. ISCR = Profit before interest and tax / Interest expense

Notes:

1.The above is an extract of the detailed format of quarter and period ended financial results filed with the Stock Exchanges in accordance with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), as amended. The full format of quarter and period ended financial results are available on the websites of the Stock exchange and the Company's website (www.ecoboxi.com).

2.For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange and the Company's website (www.ecoboxi.com).

3.The Company received the approval order dated July 17, 2025, from the Regional Director, Western Region, for the Scheme of Amalgamation under Section 233 of the Companies Act, 2013, involving the merger of Ecobox Industrials Asset II Private Limited (Transferor Company / Holding Company) with Indo Space Chittoor Private Limited (Transferee Company / Company) which is effective from November 06, 2024 (appointed date i.e. the acquisition date). The Company has completed all requisite filings with the Registrar of Companies to give effect to the scheme, in accordance with the merger order. The merger has been accounted for as a reverse acquisition in accordance with Ind AS 103 'Business Combinations', with Indo Space Chittoor II Private Limited identified as the accounting acquiree. Accordingly, comparative figures are restated to give the effect of the merger from the appointed date.

4.The above financial results of the Company are reviewed and have been approved by the Board of Directors of the Company at their respective meeting held on November 14, 2025. The Statutory Auditors have conducted limited review and have issued an unmodified report on the financial results for the quarter and period ended September 30, 2025.

For INDO SPACE CHITTOOR PRIVATE LIMITED

Ashish Shah

Director

DIN: 06898999

Date : 14 Nov, 2025

Place : Mumbai

Registered Office:
No. 258/A, Bonmasandra Industrial Area, Anekal Taluk,
Bengaluru- 560 099 , Karnataka, India.
Telephone: +91-8050009318
Email : investorrelations@narayanahealth.org

Narayana Hrudayalaya Limited

www.narayanahealth.org

CIN:L85110KA2000PLC027497

